Literature DB >> 14518430

Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002.

Howard Engers1, Marie Paule Kieny, Pawan Malhotra, J Richard Pink.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14518430     DOI： 10.1016/s0264-410x(03)00164-6

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  4 in total

1.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.

Authors:  R Saenz; C da Silva Souza; C-T Huang; M Larsson; S Esener; D Messmer
Journal:  Vaccine       Date:  2010-08-25       Impact factor: 3.641

3.  Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Authors:  Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller
Journal:  Vaccine       Date:  2010-01-04       Impact factor: 3.641

Review 4.  Vaccinology at the beginning of the 21st century.

Authors:  Andreas Wack; Rino Rappuoli
Journal:  Curr Opin Immunol       Date:  2005-08       Impact factor: 7.486
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.